Hypothesis

We hypothesize that pharmacological inhibition of the NLRP3 inflammasome in aged T cells prevents NIK‑mediated destabilization of hexokinase 2 (HK2), thereby preserving glycolytic flux and blocking the TOX‑driven epigenetic lock that defines the point of no return in T‑cell exhaustion. We're expecting that NLRP3 inhibition will break this cycle.

Mechanistic Rationale

Chronic low‑grade inflammation activates NLRP3, which amplifies both canonical and non‑canonical NF‑κB signaling. While the non‑canonical pathway via RelB directly upregulates TOX [2], NLRP3‑derived ROS and cytokine release enhance NIK activity, leading to phosphorylation‑dependent proteasomal degradation of HK2 [3]. When HK2 falls below a threshold, glycolysis collapses, ATP production drops, and the T cell shifts to a catabolic state that favors TOX expression and chromatin remodeling. In aged mice, NLRP3 activity rises with inflammaging [1], creating a feed‑forward loop that pushes CD8+ T cells past the metabolic‑epigenetic threshold marked by PD-1+/TIM-3+ low IFN‑γ phenotypes [3]. Inhibiting NLRP3 should blunt this loop, keeping NIK activity low enough to allow HK2 stabilization, maintaining glycolysis, and preventing TOX‑mediated epigenetic fixation. Don't assume that NF‑κB blockade alone is sufficient. This approach can't replace NIK‑dependent signals needed for basal survival.

Testable Predictions

1. In aged human peripheral blood CD8+ T cells, NLRP3 inhibition (using MCC950 or a specific siRNA) will increase HK2 protein levels and extracellular acidification rate (ECAR) compared with vehicle.
2. The same treatment will reduce phospho‑NIK and RelB nuclear translocation, lower TOX mRNA, and decrease PD-1/TIM-3 co‑expression after anti‑CD3/CD28 stimulation.
3. Functionally, NLRP3‑inhibited T cells will produce more IFN‑γ and exhibit greater proliferative capacity in a tumor‑co‑culture assay, whereas NIK overexpression will rescue the glycolytic defect despite NLRP3 blockade.
4. Biomarker-wise, supernatants from NLRP3‑inhibited cultures will show reduced sPD-1, IL-6, and sCD28, shifting the combined AUC for immunosenescence prediction below 0.6.

Experimental Approach

• Isolate CD8+ T cells from donors >65 years and younger controls.
• Treat with MCC950 (10 µM) or DMSO for 24 h, then stimulate with anti‑CD3/CD28 for 6 h.
• Measure HK2 by Western blot, ECAR by Seahorse, phospho‑NIK and RelB by flow cytometry, TOX by qPCR, exhaustion markers by surface staining.
• Perform IFN‑γ ELISpot and proliferation (CFSE dilution) assays.
• Include NIK overexpression via lentiviral transduction to test epistasis.
• Analyze supernatant cytokines via Luminex for sPD-1, IL-6, sCD28.
• Statistical analysis using two‑way ANOVA with post‑hoc tests.

If NLRP3 inhibition restricts HK2 loss and TOX upregulation, it will validate the notion that targeting the inflammasome upstream of NF‑κB can delay or prevent the metabolic‑epigenetic point of no return in T‑cell exhaustion during aging.